You are here: Industry Insights > COVID-19

News List

Conducting Clinical Trials amid the COVID-19 Outbreak: FDA Encourages Sponsors to Go Virtual Neeta Ratanghayra
April 08, 2020
For pharmaceutical companies, one of the most significant operational impacts of the COVID-19 is on clinical trials. On March 19, 2020, the U.S. Food and Drug Administration (FDA) issued guidance on the conduct of clinical trials during the COVID-19 pande
Pharma and Biotech Review: Treatment Options for COVID-19: Decoding the Latest Developments Neeta Ratanghayra
March 11, 2020
The Coronavirus Disease 2019 (COVID-19), which emerged in Wuhan, a city of 11 million in Hubei province, has spread to more than two dozen countries, taking the lives of more than 2,800 people.
Junshi and Eli Lilly have reached a USD 255 million COVID-19 Virus Antibody Authorization Deal CPhI.CN
May 06, 2020
On May 4, Junshi Biosciences and Eli Lilly Pharma announced that the two parties have reached an agreement to jointly develop and commercialize SARS-CoV-2 neutralizing antibodies against new coronary pneumonia caused by the new SARS-CoV-2 coronavirus.
China Disclosed Research Data of PiCoVacc, an Inactivated Virus Vaccine against COVID-19 CPhI.CN
April 21, 2020
On April 19, the Chinese Academy of Medical Sciences uploaded an article entitled "Rapid development of an inactivated vaccine for SARS-CoV-2" in BioRxiv.
Remdesivir, the First Experimental Medication to Treat 2019-novel Coronavirus (COVID-19) Infection Lin Zhang
April 23, 2020
Japan Approves Remdesivir For Use On Severe COVID-19 Patients.
Atriva Therapeutics announces publication of Proof of Concept (POC) / Phase 2a RESPIRE study data with zapnometinib in patients hospitalized with COVID-19 B3C newswire
November 06, 2023
Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, announced today the publication of proof-of-concept data for its oral MEK inhibitor.
Current COVID-19 infections in China feature low prevalence level, mild symptoms Xinhua
May 29, 2023
The overall COVID-19 infections in China have entered a low prevalence level since mid-May, and the vast majority of COVID-19 patients show mild symptoms, medical experts said.
Sinopharm announces that Paxlovid from Pfizer is Available in China PharmaSources
March 01, 2023
China National Pharmaceutical Group (Sinopharm) announced that Paxlovid from Pfizer is allowed to introduce in China. Here is the news from Pharma Sources.
Simnotrelvir Tablets/Ritonavir Tablets(co-packaged) and Deuremidevir Hydrobromide Tablets for treating COVID-19 infection approved for marketing with conditions www.nmpa.com
January 29, 2023
Simnotrelvir Tablets/Ritonavir Tablets(co-packaged) and Deuremidevir Hydrobromide Tablets for treating COVID-19 infection approved for marketing with conditions.
Biosimilar Tocilizumab Injection approved for marketing www.nmpa.com
January 16, 2023
Biosimilar Tocilizumab Injection approved for marketing.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 437 438 Next page